Treatment of Prostate Cancer
common.study.values.description
“An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer”
The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Biological - nivolumab
Specified dose on specified days
Drug - docetaxel
Specified dose on specified days
Drug - enzalutamide
Specified dose on specified days
Drug - rucaparib
Specified dose on specified days
Drug - prednisone
Specified dose on specified days
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
common.study.values.clinical-trial-id
NCT03338790
participant.views.study.view.id
nel3Jd
